+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients



Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients



Intervirology 53(3): 146-153



The authors compared the efficacies and tolerabilities of pegylated interferon-alpha2a (PEG-IFN-alpha2a) + ribavirin and pegylated interferon-alpha2b (PEG-IFN-alpha2b) + ribavirin for the initial treatment of chronic hepatitis C. A total of 126 treatment-naive patients (29.4% genotype 1, 70.6% genotype non-1) were treated with PEG-IFN-alpha2a 180 microg/week (group A, n = 79) or PEG-IFN-alpha2b 1.5 microg/kg/week (group B, n = 47) with ribavirin (800 mg/day for genotype non-1 or 1,000-1,200 mg/day for genotype 1) for 24 (genotype non-1) or 48 weeks (genotype 1). End-of-treatment virologic response, sustained virologic response, and biochemical response were not significantly different in groups A and B (84.8 vs. 89.4%, 70.9 vs. 72.3%, and 70.9 vs. 74.5%, respectively; p > 0.05). In patients with the HCV genotype 1 or non-1, treatment responses were not significantly different. Multivariate analysis showed that HCV genotype only was an independent factor that affected sustained virologic response (p = 0.048). The proportions of treatment discontinuations in groups A and B were similar (10.1 vs. 10.6%; p = 1.000). PEG-IFN-alpha2a or PEG-IFN-alpha2b + ribavirin combination therapies showed similar efficacies and tolerabilities as initial treatments for chronic hepatitis C.

(PDF emailed within 0-6 h: $19.90)

Accession: 052897896

Download citation: RISBibTeXText

PMID: 20068348

DOI: 10.1159/000274975


Related references

A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Alimentary Pharmacology and Therapeutics 24(7): 1079-1086, 2006

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy). Journal of Medical Virology 82(12): 2027-2031, 2011

Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment. Gut and Liver 1(1): 87-89, 2007

Pegylated Interferon alpha2b plus ribavirin in non responder and naive chronic hepatitis C patients. Hepatology 36(4 Part 2): 596A, 2002

Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. Journal of Antimicrobial ChemoTherapy 63(6): 1256-1263, 2009

Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. Aids Research and Human Retroviruses 22(4): 315-320, 2006

Retreatment with pegylated interferon alpha2b plus ribavirin in patients with chronic hepatitis c not responding to a previous antiviral treatment with standard interferons combined with ribavirin. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1216, 2003

Effects of HCV treatment on HIV course Preliminary results of the ANRS HC 02-ribavic study A randomized, controlled trial of pegylated interferon-alpha2b with ribavirin vs interferon-alpha2b with ribavirin for the treatment of chronic HCV in HIV co-infection. Hepatology 36(4 Part 2): 585A, 2002

Controlled trial with pegylated interferon-alpha2b plus ribavirin retreatment in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin. Journal of Hepatology 38(Supplement 2): 176, 2003

Pegylated interferon alpha2b versus pegylated interferon alpha2a for chronic hepatitis C: the unreached goal of superiority. Journal of Hepatology 51(6): 1097-1099, 2009

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. Journal of Viral Hepatitis 12(3): 292-299, 2005

A 3-arm randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 MU both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naive patients with chronic HCV hepatitis. Journal of Hepatology 36(Supplement 1): 117, 2002

Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis. Drugs 73(3): 263-277, 2013

Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b. Antiviral Therapy 13(4): 511-517, 2008

Retreatment with pegylated interferon alpha-2b and ribavirin in patients with chronic hepatitis C non responders to interferon monotherapy or interferon and ribavirin combination A prospective randomized pilote study of two regimens Induction versus reg. Journal of Hepatology 40(Suppl 1): 135, 2004